Lee Young-Ho
Department of Pediatrics, Hanyang University College of Medicine, Seoul, Korea.
Korean J Pediatr. 2014 Mar;57(3):110-6. doi: 10.3345/kjp.2014.57.3.110. Epub 2014 Mar 31.
Cord blood (CB) has been used as an important and ethical source for hematopoietic stem cell transplantation (SCT) as well as cell therapy by manufacturing mesenchymal stem cell, induced pleuripotential stem cell or just isolating mononuclear cell from CB. Recently, the application of cell-based therapy using CB has expanded its clinical utility, particularly, by using autologous CB in children with refractory diseases. For these purposes, CB has been stored worldwide since mid-1990. In this review, I would like to briefly present the historical development of clinical uses of CB in the fields of SCT and cell therapy, particularly to review the experiences in Korea. Furthermore, I would touch the recent banking status of CB.
脐带血(CB)已成为造血干细胞移植(SCT)以及细胞治疗的重要且符合伦理的来源,通过制造间充质干细胞、诱导多能干细胞,或者仅从脐带血中分离单个核细胞来实现。最近,使用脐带血进行的细胞治疗应用扩大了其临床用途,特别是在难治性疾病儿童中使用自体脐带血。出于这些目的,自20世纪90年代中期以来,脐带血已在全球范围内储存。在本综述中,我想简要介绍脐带血在SCT和细胞治疗领域临床应用的历史发展,特别是回顾韩国的经验。此外,我还将探讨脐带血最近的储存情况。